Satraplatin (BMS-182751, BMY-45594, JM-216) is a platinum-based antineoplastic agent that binds to guanine residues in DNA, inhibits DNA replication and transcription, leads to subsequent apoptosis.

SAS-0132 (SAS132) is a novel potent, subtype-selective, brain penetrant sigma 2 receptor/PGRMC1 ligand with Ki of 90 nM, 9-fold selectivity over sigma 1 receptors.

SAR407899 Hcl is a potent, ATP-competitive ROCK inhibitor woth Ki value of 36 nM/41 nM for human ROCK/Rat ROCK respectively.

SAR260301 (SAR-260301, SAR 260301) is a potent, selective, ATP-competitive PI3Kβ inhibitor with IC50 of 52 nM in TR-FRET assays, with littile to no actiivty against PI3Kα/γ/δ (IC50=1,869/>10,000/403 nM, respectively).

SAR-216471 is a potent, highly selective, intravenous and oral, reversible P2Y12 receptor antagonist with binding IC50 of 17 nM.

Sapropterin Dihydrochloride, a synthetic preparation of the dihydrochloride salt of naturally occurring tetrahydrobiopterin (BH4), is a phenylalanine hydroxylase activator.

SAN9812 (Carnostatine) is a potent, highly selective, competitive inhibitor of Carnosinase 1 (CN1) activity with Ki of 11 nM.

San78-130 is a potent, selective activin receptor-like Kinase 1 (ALK1) inhibitor with IC50 of 62 nM, with greater selectivity compared with L-783277.

SAMT-247 potent HIV-1 nucleocapsid protein NCp7 inhibitor with EC50 of 0.6 uM with low cellular toxicity (TC50>100 uM) in cultured and primary cells.

Samatasvir (IDX719) is a highly potent, selective inhibitor of HCV NS5A that effectively inhibits HCV genotype 1-5 replicons with EC50 of 2-24 pM.

Salvianolic acid A acts as scavengers of reactive oxygen species, reduces the adherence of leukocytes to endothelial cells, inhibits matrix metalloproteinases and inflammation.

SAK3 (T-VGCC enhancer SAK3) is a potent, orally acitve enhancer of T-type voltage-gated Ca2+ channel (T-VGCC), enhances CaV3.1 and CaV3.3, but not CaV3.2 activity at concentrations of 0.01-10 nM in neuro2A cells in vitro.

sAJM-589 is a novel, potent small molecule Myc inhibitor that disrupts the Myc-Max leucine-zipper heterodimer with IC50 of 1.8 uM.

Safinamide (EMD 1195686; FCE 26743) selectively and reversibly inhibits MAO-B with IC50 of 98 nM, exhibits 5918-fold selectivity against MAO-A.

SA 47 is a selective and potent inhibitor of fatty acid amide hydrolase (FAAH) and carbamate.

S55746 hydrochloride is a potent, orally active and selective BCL-2 inhibitor, with Kis and Kds of 1.3 nM, 520 nM and 3.9 nM, 186 nM for BCL-2 and BCL-XL, respectively. S55746 hydrochloride has antitumor activity.

S44819 (S 44819, Egis-13529) is a novel potent, competitive, selective antagonist of the α5-GABAAR with Kd of 221 nM, IC50 of 585 nM (α5β2γ2).

S44563 is a potent, dual Bcl-2/Bcl-XL inhibitor with IC50 of 131 and 140 nM, respectively.

S3I-M2001 (Bromohydroxyacetone phosphate) is an oxazole-based peptidomimetic of the STAT3 SH2 domain-binding phosphotyrosine peptide that selectively disrupts active STAT3:STAT3 dimers.

S-3448 is a potent, specific soluble guanylate cyclase (sGC) activator with EC50 of 0.68 uM, preferentially activates the NO-insensitive heme-oxidized form of sGC.

S-2101 is a potent lysine-specific demethylase 1 (LSD1) inhibitor with Ki of 0.61 uM.

S1P1 Agonist 8 is a potent, selective, orally bioavailable S1P1 receptor agonist with EC50 of 35 nM (S1P1 internalization), >100-fold selectivity over against receptor subtypes S1P2-5.

S1p receptor agonist 1 is an S1P receptor agonist extracted from patent WO 2015039587 A1, compound example 2.

S130 (ATG4B inhibitor S130) is a potent, specific ATG4B inhibitor with IC50 of 3.24 uM, shows strong affinity (Kd=4 uM) and specifically suppresses the activity of ATG4B, but not other proteases.

Ryanodine is a cell permeant ryanodine receptor modulator. Ryanodine can either stimulate or inhibit Ryanodine-mediated Ca2+ release depending on its concentrations. Poisonous diterpenoid found in Ryania speciosa.

RVX-297 is a novel orally active, BD2 selective, BET bromodomain inhibitor with Alpha Screen IC50 of 0.08, 0.05 and 0.02 uM for BRD2 (BD2), BRD3 (BD2) and BRD4 (BD2), respectively.

RVX2135 is a novel potent and orally bioavailable inhibitor of Brd2, Brd3, Brd4, and BrdT with IC50 of 1.31, 0.58, 0.44, and 1.58 uM, respectively.

RV-1729 is a potent, selective PI3Kδ inhibitor with IC50 of 12 nM, 2-fold selectivity for PI3Kδ relative to PI3Kγ and 16-fold over PI3Kα.

RV1088 is a potent narrow spectrum kinase inhibitor that target p38, c-Src, Syk or JAK individually, dose-dependently reduces TNF-α levels in LPS-activated macrophages with IC50 of 0.63 nM.

Rutin hydrate is a flavonol glycoside, able to cross the blood-brain barrier, and acts by inhibiting JNK and ERK1/2 activation and activating mTOR signalling.